UP!
 |
|
|
Type
|
Public (NASDAQ: HALO) |
|---|---|
| Industry | Biopharmaceutical |
| Founded | 1998 |
| Headquarters | San Diego, California, USA |
|
Key people
|
Dr. Helen Torley, President & CEO |
| Products | Biologics |
| Revenue |  $ 3,799,521 USD (2007) |
|
Number of employees
|
150 |
| Slogan | ' |
| Website | www.halozyme.com |
Halozyme Therapeutics, based in San Diego, California, is a biopharmaceutical company developing and commercializing novel oncology and drug delivery therapies.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-10-31 | Future report Set alerts | |
| Q2 2022 | 2022-08-09 | 0.53 | 0.53 |
| Q1 2022 | 2022-05-10 | 0.47 | 0.47 |
| Q4 2021 | 2022-02-22 | 0.42 | 0.42 |
| Q3 2021 | 2021-11-02 | 1.48 | 1.48 |
| Q2 2021 | 2021-08-09 | 0.62 | 0.62 |
| Q1 2021 | 2021-05-10 | 0.19 | 0.19 |
| Q4 2020 | 2021-02-23 | 0.50 | 0.50 |
| Q3 2020 | 2020-11-02 | 0.25 | 0.25 |
| Q2 2020 | 2020-08-10 | 0.19 | 0.19 |
| 2016-06-23 | Reiterated Rating | Piper Jaffray | Overweight | $15.00 |
| 2016-06-23 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $15.00 |
| 2016-06-09 | Reiterated Rating | Piper Jaffray | Overweight | $15.00 |
| 2016-06-08 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-06-08 | Reiterated Rating | Wells Fargo & Co. | Buy | |
| 2016-06-06 | Reiterated Rating | Canaccord Genuity | Buy | $11.00 |
| 2016-05-10 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-05-10 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-05-10 | Reiterated Rating | Jefferies Group | Sell | $6.75 |
| 2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $22.00 to $20.00 |
| 2016-02-24 | Lower Price Target | Barclays | Overweight | $27.00 to $16.00 |
| 2016-02-24 | Lower Price Target | Barclays PLC | Overweight | $27.00 to $16.00 |
| 2016-02-01 | Initiated Coverage | Canaccord Genuity | Buy | $10.00 |
| 2016-01-26 | Reiterated Rating | Piper Jaffray | Overweight | $24.00 to $20.00 |
| 2015-12-04 | Initiated Coverage | Wells Fargo | Outperform | |
| 2015-11-18 | Initiated Coverage | Citigroup Inc. | Buy | $25.00 |
| 2015-09-22 | Initiated Coverage | Barclays | Overweight to Overweight | $27.00 |
| 2015-09-15 | Reiterated Rating | Piper Jaffray | Buy | $24.00 |
| 2015-08-11 | Reiterated Rating | JMP Securities | Buy | $21.00 to $22.00 |
| 2015-06-22 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $20.00 to $25.00 |
| 2015-06-05 | Reiterated Rating | Piper Jaffray | Overweight | $19.00 to $21.00 |
| 2015-06-04 | Boost Price Target | JMP Securities | Buy | $17.00 to $21.00 |
| 2015-06-01 | Reiterated Rating | MLV & Co. | Buy | $20.00 |
| 2015-04-20 | Set Price Target | BMO Capital Markets | Buy | $26.00 |
| 2015-04-08 | Reiterated Rating | MLV & Co. | Buy | |
| 2015-03-03 | Initiated Coverage | MLV & Co. | Buy | $20.00 |
| 2015-03-03 | Boost Price Target | BMO Capital Markets | Buy | $24.00 to $26.00 |
| 2015-02-18 | Boost Price Target | MLV & Co. | Buy | $15.00 to $20.00 |
| 2015-01-08 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $12.00 to $16.00 |
| 2015-01-08 | Boost Price Target | Piper Jaffray | $17.00 | |
| 2015-01-02 | Initiated Coverage | MLV & Co. | Buy | $12.00 to $15.00 |
| 2014-12-24 | Initiated Coverage | MLV & Co. | Buy | $12.00 |
| 2014-12-09 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $13.00 to $12.00 |
| 2014-09-15 | Reiterated Rating | Jefferies Group | Underperform | $4.50 to $5.00 |
| 2014-07-11 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $13.00 |
| 2014-04-15 | Initiated Coverage | Citigroup Inc. | Buy | $12.00 |
| 2014-04-04 | Reiterated Rating | BMO Capital Markets | Buy | |
| 2014-01-27 | Boost Price Target | Jefferies Group | $4.00 to $4.50 | |
| 2014-01-10 | Reiterated Rating | Barclays | Equal Weight | $12.00 to $15.00 |
| 2013-11-11 | Boost Price Target | BMO Capital Markets | $13.00 to $17.00 | |
| 2013-11-11 | Boost Price Target | Barclays | Equal Weight | $8.00 to $12.00 |
| 2011-10-18 | Upgrade | JMP Securities | Mkt Perform to Mkt Outperform | $9 |
| 2010-10-06 | Initiated | Barclays Capital | Overweight | $12 |
| 2010-04-08 | Initiated | William Blair | Outperform | |
| 2010-03-22 | Upgrade | Brean Murray | Hold to Buy | $13 |
| 2009-10-13 | Upgrade | Wedbush Morgan | Neutral to Outperform | $7 to $10 |
| 2009-04-21 | Initiated | Wedbush Morgan | Buy | $7 |
| 2009-02-26 | Initiated | Merriman Curhan Ford | Buy | |
| 2008-03-17 | Reiterated | Roth Capital | Hold | $9 to $6 |
| 2016-06-23 | Reiterated Rating | Piper Jaffray | Overweight | $15.00 |
| 2016-06-23 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $15.00 |
| 2016-06-09 | Reiterated Rating | Piper Jaffray | Overweight | $15.00 |
| 2016-06-08 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-06-08 | Reiterated Rating | Wells Fargo & Co. | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In HALO 289 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 18.20M |
| Vanguard Group, Inc | 13.34M |
| STATE STREET CORP | 6.17M |
| Artisan Partners Limited Partnership | 6.13M |
| Invesco Ltd. | 5.64M |
| BlackRock Fund Advisors | 5.09M |
| SNYDER CAPITAL MANAGEMENT L P | 4.42M |
| JPMORGAN CHASE & CO | 3.93M |
| BlackRock Institutional Trust Company, N.A. | 3.04M |
| MACQUARIE GROUP LTD | 2.55M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.48M |
| GANNETT WELSH & KOTLER | 2.20M |
| LOOMIS SAYLES & CO L P | 2.15M |
| NORTHERN TRUST CORP | 2.12M |
| GOLDMAN SACHS GROUP INC | 1.66M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Frost Gregory Ian VP, Chief Scientific Officer | 2.91% (3641380) | HALO / XON / |
| KIRK RANDAL J | 1.86% (2327603) | APHB / HALO / OGEN / SNGX / SYN / TBIO / TGEN / XON / ZIOP / |
| Lim Jonathan E Chief Executive Officer | 0.57% (710000) | HALO / RXDX / |
| RAMSAY DAVID A VP and Chief Financial Officer | 0.29% (364320) | HALO / MSTX / |
| FALBERG KATHRYN E | 0.29% (358253) | ABIO / BMRN / HALO / JAZZ / MDVN / |
| Torley Helen President and CEO | 0.26% (329486) | HALO / RLYP / |
| Engler Robert | 0.22% (273176) | HALO / |
| MATSUI CONNIE | 0.19% (242751) | HALO / |
| Kelley Kenneth J | 0.17% (212751) | HALO / |
| PATTON JOHN STUART | 0.14% (179876) | HALO / |
| Posard Matthew L. | 0.08% (102751) | HALO / TROV / |
| BIZZARI JEAN-PIERRE | 0.05% (61312) | CPXX / HALO / |
| Shaffer James P VP & Chief Commercial Officer | 0.04% (54025) | CLDN / HALO / |
| Henderson Jeffrey William | 0.04% (51105) | CAH / FGEN / HALO / QCOM / |
| Stelzer Laurie SVP, CFO | 0.04% (47510) | HALO / |
| Countouriotis Athena SVP and Chief Medical Officer | 0.04% (45977) | AAVL / AMBI / HALO / TROV / |
| Daly James M | 0.04% (44700) | ACAD / CMRX / HALO / INCY / |
| LEONHARDT HARRY J SVP, GC and CCO | 0.03% (39558) | HALO / |
| GUSTAFSON KURT A Vice President and CFO | 0.03% (35667) | HALO / SPPI / XNCR / |
| LIU JEAN I VP & General Counsel | 0.02% (20869) | DRRX / HALO / SGEN / |
| Shepard H. Michael VP, Chief Scientific Officer | 0.01% (13198) | HALO / |
UM